Journal Article

Tirzepatide prevents neurodegeneration through multiple molecular pathways

Paolisso, Giuseppe, Pesapane, Ada, Tortorella, Giovanni, Taktaz, Fatemeh, Barbieri, Michelangela, Ghosh, Puja, Scisciola, Lucia, Feliciano, Maria Federica, Fontanella, Rosaria Anna, Puocci, Armando, Franzese, Martina, Sommella, Eduardo, Ambrosino, Concetta

2024

Overview

Background Several evidence demonstrated that glucagon-like peptide 1 receptor agonists (GLP1-RAs) reduce the risk of dementia in type 2 diabetes patients by improving memory, learning, and overcoming cognitive impairment. In this study, we elucidated the molecular processes underlying the protective effect of Tirzepatide (TIR), a dual glucose-dependent insulinotropic polypeptide receptor agonist (GIP-RA)/ GLP-1RA, against learning and memory disorders. Methods We investigated the effects of TIR on markers of neuronal growth (CREB and BDNF), apoptosis (BAX/Bcl2 ratio) differentiation (pAkt, MAP2, GAP43, and AGBL4), and insulin resistance (GLUT1, GLUT4, GLUT3 and SORBS1) in a neuroblastoma cell line (SHSY5Y) exposed to normal and high glucose concentration. The potential role on DNA methylation of genes involved in neuroprotection and epigenetic modulators of neuronal growth (miRNA 34a), apoptosis (miRNA 212), and differentiation (miRNA 29c) was also investigated. The cell proliferation was detected by measuring Ki-67 through flow cytometry. The data were analysed by SPSS IBM Version 23 or GraphPad Prism 7.0 software and expressed as the means ± SEM. Differences between the mean values were considered significant at a p-value of < 0.05. GraphPad Prism software was used for drawing figures. Results For the first time, it was highlighted: (a) the role of TIR in the activation of the pAkt/CREB/BDNF pathway and the downstream signaling cascade; (b) TIR efficacy in neuroprotection; (c) TIR counteracting of hyperglycemia and insulin resistance-related effects at the neuronal level. Conclusions We demonstrated that TIR can ameliorate high glucose-induced neurodegeneration and overcome neuronal insulin resistance. Thus, this study provides new insight into the potential role of TIR in improving diabetes-related neuropathy. Graphical Abstract

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Agonists / Alzheimer's disease / Analysis / Antibodies / Antidiabetics / Apoptosis / BAX protein / Bcl-2 protein / Biomedical and Life Sciences / Biomedicine / Brain-derived neurotrophic factor / Care and treatment / Cell culture / Cell growth / Cell proliferation / Cognitive ability / Cyclic AMP response element-binding protein / Dementia / Dementia disorders / Diabetes mellitus (non-insulin dependent) / Diabetes mellitus type 2 / Diagnosis / DNA methylation / Dosage and administration / Epigenetics / Flow cytometry / GIP protein / GLP-1 receptor agonists / Glucagon / Glucagon-like peptide 1 / Glucose / Glucose homeostasis / Hyperglycemia / Hypoglycemic agents / Insulin resistance / Laboratories / Learning / Medicine/Public Health / Memory / MicroRNAs / miRNA / Neuroblastoma / Neurodegeneration / Neurodegenerative diseases / Neurodifferentiation / Neuromodulation / Neuronal growth / Neuropathy / Neuroprotection / Peptides / Physiology, Pathological / Prevention / Proteins / Risk factors / Software / Translational Signaling and System Biology